February 1, 2026 at 4:58 AM
@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday
May 30, 2026 at 9:38 PM
@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday
New data at #ASCO2026 suggest darolutamide may be easier on the brain than enzalutamide. Dr Alicia Morgans discusses results from ARACOG trial, patients with advanced #ProstateCancer who experienced significantly less cognitive decline with darolutamide. ecancer.org/en/video/129...
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer - ecancer
Dr Morgans talks to ecancer at ASCO 2026 about results she presented from the phase 2 ARACOG (AFT-47) randomized trial.
Darolutamide was associated with sign
ecancer.org
May 30, 2026 at 10:25 PM
New data at #ASCO2026 suggest darolutamide may be easier on the brain than enzalutamide. Dr Alicia Morgans discusses results from ARACOG trial, patients with advanced #ProstateCancer who experienced significantly less cognitive decline with darolutamide. ecancer.org/en/video/129...
Two Alliance oral abstracts are being presented today at #ASCO26. Atish Choudhury, MD, PhD, presents A-DREAM (A032101), and Alicia Morgans, MD, MPH, presents ARACOG (AFT-47), a randomized trial comparing cognitive outcomes with darolutamide versus enzalutamide. #NCI #NCTN #CancerResearch #GUOnc
May 30, 2026 at 12:32 PM
Two Alliance oral abstracts are being presented today at #ASCO26. Atish Choudhury, MD, PhD, presents A-DREAM (A032101), and Alicia Morgans, MD, MPH, presents ARACOG (AFT-47), a randomized trial comparing cognitive outcomes with darolutamide versus enzalutamide. #NCI #NCTN #CancerResearch #GUOnc
WATCH: Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer. #oncology #pcsm #prostatecancer www.onclive.com/view/dr-morg...
Dr Morgans on the Clinical Significance of Data From the ARACOG Trial in Prostate Cancer | OncLive
Alicia Morgans, MD, MPH, discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer.
www.onclive.com
June 26, 2026 at 6:05 PM
WATCH: Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses the clinical significance of data from the phase 2 ARACOG trial in prostate cancer. #oncology #pcsm #prostatecancer www.onclive.com/view/dr-morg...
WATCH: Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial. #oncology #pcsm #prostatecancer www.onclive.com/view/dr-morg...
Dr Morgans on the Cognitive Effects of Darolutamide Vs Enzalutamide in Prostate Cancer | OncLive
Alicia Morgans, MD, MPH, discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial.
www.onclive.com
June 25, 2026 at 2:16 PM
WATCH: Alicia Morgans, MD, MPH, of @danafarber.bsky.social discusses data on the cognitive effects of enzalutamide vs darolutamide in prostate cancer from the ARACOG trial. #oncology #pcsm #prostatecancer www.onclive.com/view/dr-morg...